This appointment is based on a press release statement and reflects Phibro’s commitment to enhancing its governance and strategic oversight as the company continues to serve a wide range of stakeholders in the animal health domain. InvestingPro analysis shows the company has delivered impressive returns, with the stock up over 103% in the past year. Subscribers can access additional insights and 6 more ProTips about PAHC’s financial outlook through InvestingPro’s comprehensive research reports. InvestingPro analysis shows the company has delivered impressive returns, with the stock up over 103% in the past year. Subscribers can access additional insights and 6 more ProTips about PAHC’s financial outlook through InvestingPro’s comprehensive research reports.
With the addition of Ms. Lee, the Board now comprises nine directors, six of whom hold independent status. Her background includes leadership roles at Cobb Vantress LLC, Elanco, Bayer (OTC:BAYRY) Animal Health, and Zoetis (NYSE:ZTS). Lee’s career has spanned various functions such as general management, strategy, and R&D, demonstrating a broad skill set in the sector.
Her industry contributions have been recognized with accolades like the Feather in Her Cap Award in 2018. Lee also brings governance experience, having served on corporate governance and nomination committees, as well as audit committees for other publicly traded companies.
Jack Bendheim, Phibro’s Chairman, President, and CEO, expressed enthusiasm for Lee’s appointment, noting her proven track record in value creation for leading brands in the animal health industry.
This appointment is based on a press release statement and reflects Phibro’s commitment to enhancing its governance and strategic oversight as the company continues to serve a wide range of stakeholders in the animal health domain.
In other recent news, Phibro Animal Health (NASDAQ:PAHC) Corporation reported a robust start to its fiscal year 2025, with consolidated net sales for the first quarter reaching $260.4 million, marking a 13% increase year-over-year. The company’s Animal Health segment witnessed significant growth, with vaccine sales rising by 22%. Adjusted EBITDA and net income also reported substantial increases. Phibro has updated its fiscal year 2025 guidance, projecting a rise in net sales, EBITDA, and net income. The recently acquired Zoetis Medicated Feed Additive business is expected to contribute meaningfully to the company’s revenue and margins. These are among the recent developments for Phibro. The company anticipates continued favorable momentum in its business and expects net income to grow by 14% to 24%. The integration of the Zoetis MFA acquisition remains a focus, with expected enhancements to Phibro’s performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.